ALM
MCID: ACR014
MIFTS: 51

Acral Lentiginous Melanoma (ALM)

Categories: Cancer diseases, Rare diseases, Skin diseases

Aliases & Classifications for Acral Lentiginous Melanoma

MalaCards integrated aliases for Acral Lentiginous Melanoma:

Name: Acral Lentiginous Melanoma 12 53 15
Acral Lentiginous Malignant Melanoma of Skin 53
Acral Lentiginous Melanoma, Malignant 12
Malignant Acral Lentiginous Melanoma 12
Acral Lentiginous Malignant Melanoma 73
Palmar/plantar Melanoma 53
Subungual Melanoma 53
Alm 53

Classifications:



External Ids:

Disease Ontology 12 DOID:6367
UMLS 73 C0346037

Summaries for Acral Lentiginous Melanoma

NIH Rare Diseases : 53 Acral lentiginous melanoma (ALM) is a type of melanoma that occurs on the palms of the hands or the soles of the feet. The condition can develop in normal-appearing skin or within an existing mole. ALM begins as a flat patch of discolored skin that may enlarge slowly over time. Although the cancercells often remain contained at the skins surface (epidermis) initially, ALM can become invasive and spread as the condition advances. Like other flat forms of melanoma, it can be recognized by the ABCDE rule. Although ALM affects men and women of all skin colors equally, is it most commonly diagnosed in people over age 40. The underlying cause of ALM is poorly understood. It is not related to sun exposure like other forms of skin cancer. Initial treatment generally consists of surgery to remove the skin lesion. Additional therapy (such as radiation therapy or immunotherapy) may then be recommended depending on the severity of the condition.

MalaCards based summary : Acral Lentiginous Melanoma, also known as acral lentiginous malignant melanoma of skin, is related to melanoma and mucosal melanoma, and has symptoms including macule An important gene associated with Acral Lentiginous Melanoma is NRAS (NRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are ERK Signaling and Apoptotic Pathways in Synovial Fibroblasts. The drugs Aredia and Bromfenac have been mentioned in the context of this disorder. Affiliated tissues include skin, brain and lung, and related phenotypes are Decreased substrate adherent cell growth and Decreased substrate adherent cell growth

Disease Ontology : 12 A skin melanoma that is characterized by slow growth of a small pigmented spot on the skin with a clearly defined edge, surrounded by normal-appearing skin and occurs on occurs on non hair-bairing surfaces including hands and feet, subungual sites, and fingers or toes.

Wikipedia : 76 Acral lentiginous melanoma is a kind of lentiginous skin melanoma. Melanoma is a serious skin cancer... more...

Related Diseases for Acral Lentiginous Melanoma

Diseases related to Acral Lentiginous Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 109)
# Related Disease Score Top Affiliating Genes
1 melanoma 31.2 BRAF CDKN2A NRAS PTEN
2 mucosal melanoma 29.7 BRAF KIT NRAS TERT
3 myeloma, multiple 29.6 BRAF CDKN2A KIT NRAS
4 squamous cell carcinoma 29.5 BRAF CDKN2A PTEN
5 alstrom syndrome 11.4
6 sarcoma 10.3
7 conventional fibrosarcoma 10.1 KIT NRAS
8 malignant spindle cell melanoma 10.1 KIT NRAS
9 bowenoid papulosis 10.1 CDKN2A TERT
10 basal cell carcinoma 1 10.1
11 psoriatic arthritis 10.1
12 arthritis 10.1
13 nodular malignant melanoma 10.1
14 tinea pedis 10.1
15 phaeohyphomycosis 10.1
16 basal cell carcinoma 10.1
17 palmoplantar keratosis 10.1
18 clear cell sarcoma 10.1
19 tinea nigra 10.1
20 lichen planus 10.1
21 degos 'en cocarde' erythrokeratoderma 10.1
22 lentigo maligna melanoma 10.1
23 lichen planus pigmentosus 10.1
24 superficial spreading melanoma 10.1
25 congenital mesoblastic nephroma 10.1 KIT NRAS
26 melanomatosis 10.1 CDKN2A NRAS
27 malignant skin fibrous histiocytoma 10.1 KIT NRAS
28 core binding factor acute myeloid leukemia 10.1 KIT NRAS
29 malignant dermis tumor 10.1 KIT NRAS
30 meningeal melanomatosis 10.1 CDKN2A NRAS
31 mixed type thymoma 10.1 KIT PTEN
32 adenoid basal cell carcinoma 10.1 CDKN2A KIT
33 lymphoepithelioma-like thymic carcinoma 10.1 CDKN2A KIT
34 meningeal melanocytoma 10.1 CDKN2A NRAS
35 sarcomatoid renal cell carcinoma 10.1 KIT PTEN
36 prostate small cell carcinoma 10.1 KIT PTEN
37 ewing's family of tumors 10.1 CDKN2A KIT
38 necrotizing sialometaplasia 10.1 CDKN2A KIT
39 cervical intraepithelial neoplasia 10.1 CDKN2A TERT
40 tonsil cancer 10.1 CDKN2A KIT
41 fibrosarcoma of bone 10.1 CDKN2A KIT
42 cutaneous leishmaniasis 10.1
43 leishmaniasis 10.1
44 oropharynx cancer 10.0 CDKN2A KIT
45 spinal chordoma 10.0 MET TERT
46 pharynx cancer 10.0 CDKN2A KIT
47 undifferentiated pleomorphic sarcoma 10.0 KIT MET
48 endometrial squamous cell carcinoma 10.0 CDKN2A MET
49 neurofibroma 10.0 CDKN2A KIT
50 bladder disease 10.0 CDKN2A TERT

Graphical network of the top 20 diseases related to Acral Lentiginous Melanoma:



Diseases related to Acral Lentiginous Melanoma

Symptoms & Phenotypes for Acral Lentiginous Melanoma

UMLS symptoms related to Acral Lentiginous Melanoma:


macule

GenomeRNAi Phenotypes related to Acral Lentiginous Melanoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 9.23 KIT MET
2 Decreased substrate adherent cell growth GR00193-A-2 9.23 KIT
3 Decreased substrate adherent cell growth GR00193-A-3 9.23 BRAF MET
4 Decreased substrate adherent cell growth GR00193-A-4 9.23 BRAF KIT MET

MGI Mouse Phenotypes related to Acral Lentiginous Melanoma:

46 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.14 BRAF CDKN2A KIT MET NRAS PTEN
2 digestive/alimentary MP:0005381 10.14 BRAF CDKN2A KIT MET NRAS PTEN
3 endocrine/exocrine gland MP:0005379 10.12 BRAF CDKN2A KIT MET NRAS PTEN
4 growth/size/body region MP:0005378 10.11 BRAF CDKN2A KIT MET NRAS PTEN
5 behavior/neurological MP:0005386 10.09 BRAF CDKN2A KIT MET NRAS PTEN
6 homeostasis/metabolism MP:0005376 10.09 BRAF CDKN2A KIT MET NRAS PTEN
7 cardiovascular system MP:0005385 10.08 BRAF CDKN2A KIT MET NRAS PTEN
8 immune system MP:0005387 10.08 BRAF CDKN2A KIT MET NRAS PTEN
9 embryo MP:0005380 10.06 BRAF CDKN2A KIT MET NRAS PTEN
10 hematopoietic system MP:0005397 10.03 BRAF CDKN2A KIT NRAS PTEN TERT
11 mortality/aging MP:0010768 10.02 BRAF CDKN2A KIT MET NRAS PTEN
12 neoplasm MP:0002006 9.98 BRAF CDKN2A KIT MET NRAS PTEN
13 liver/biliary system MP:0005370 9.97 BRAF CDKN2A KIT MET NRAS PTEN
14 integument MP:0010771 9.92 BRAF CDKN2A KIT NRAS PTEN
15 limbs/digits/tail MP:0005371 9.91 BRAF KIT MET NRAS PTEN
16 nervous system MP:0003631 9.88 BRAF CDKN2A KIT MET PTEN TERT
17 muscle MP:0005369 9.85 BRAF CDKN2A KIT MET PTEN
18 normal MP:0002873 9.85 BRAF KIT MET NRAS PTEN TERT
19 pigmentation MP:0001186 9.72 BRAF CDKN2A KIT NRAS PTEN
20 reproductive system MP:0005389 9.65 BRAF CDKN2A KIT PTEN TERT
21 respiratory system MP:0005388 9.63 BRAF CDKN2A KIT MET PTEN TERT
22 skeleton MP:0005390 9.43 BRAF CDKN2A KIT NRAS PTEN TERT
23 vision/eye MP:0005391 9.1 BRAF CDKN2A KIT MET NRAS PTEN

Drugs & Therapeutics for Acral Lentiginous Melanoma

FDA approved drugs:

(show top 50) (show all 63)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Aredia 18 49 PAMIDRONATE DISODIUM Chiron August 1996
2
Bromfenac 18 BROMFENAC SODIUM Duract, Wyeth-Ayerst Laboratories July 1997
3
Cervarix 18 49 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline October 2009
4
Cometriq 18 49 CABOZANTINIB S-MALATE Exelixis November 2012
5
Gardasil 18 49 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006
6
Inlyta 18 49 AXITINIB Pfizer January 2012
7
Ixempra 18 49 IXABEPILONE Bristol-Myers Squibb October 2007
8
Lenvima 18 49 LENVATINIB MESYLATE Eisai February 2015
9
Lupron Depot 18 49 LEUPROLIDE ACETATE TAP Pharmaceuticals/ Abbott Laboratories July 1997/ January 1996
10
Self-examination breast pad 18 Inventive Products on December 22, 1995
11
Stivarga 18 49 REGORAFENIB Bayer/ Bayer HealthCare Pharmaceuticals February 2013/ September 2012
12
Tafinlar 18 49 DABRAFENIB MESYLATE GlaxoSmithKline May 2013
13
Temodar 18 49 TEMOZOLOMIDE Schering-Plough August 1999
14
Tykerb 18 49 LAPATINIB DITOSYLATE GlaxoSmithKline March 2007
15
Velcade 18 49 BORTEZOMIB Millennium Pharmaceuticals May 2003
16
Xeloda 18 49 CAPECITABINE Roche April 1998/ May 2001
17
Adcirca 18 TADALAFIL Eli Lilly May 2009
18
Advair 18 FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE GlaxoSmithKline August 2000
19
Arcapta 18 INDACATEROL MALEATE Novartis July 2011
20
Augmentin 18 AMOXICILLIN; CLAVULANATE POTASSIUM SmithKline Beecham February 1996
21
Azmacort 18 TRIAMCINOLONE ACETONIDE Rhone Poulenc Rorer November 1996
22
Breathe Right 18 CNS June 1996
23
Brovana 18 ARFORMOTEROL TARTRATE Sepracor in October 2006
24
Cafcit Injection 18 CAFFEINE CITRATE Roxane Laboratories September 1999
25
Cedax 18 CEFTIBUTEN DIHYDRATE Schering-Plough December 1995
26
Cefazolin and Dextrose USP 18 CEFAZOLIN SODIUM B Braun Medical July 2000
27
Claritin RediTabs 18 LORATADINE Schering-Plough January 1997
28
Claritin-D 24 Hour Extended Release Tablets 18 LORATADINE; PSEUDOEPHEDRINE SULFATE Schering-Plough August 1996
29
Covera-HS 18 VERAPAMIL HYDROCHLORIDE GD Searle, Alza January 1996
30
Daliresp 18 ROFLUMILAST Forest Pharmaceuticals February 2011
31
Dulera 18 FORMOTEROL FUMARATE; MOMETASONE FUROATE Merck June 2010
32
Esbriet 18 PIRFENIDONE InterMune October 2014
33
Grastek 18 Timothy Grass Pollen Allergen Extract Merck April 2014
34
Iressa 18 GEFITINIB AstraZeneca May 2003
35
Letairis 18 AMBRISENTAN Gilead June 2007
36
Nucala 18 MEPOLIZUMAB GlaxoSmithKline November 2015
37
Opdivo 18 NIVOLUMAB Bristol-Myers Squibb March 2015
38
Oralair 18 Greer Labs April 2014
39
Patanase 18 OLOPATADINE HYDROCHLORIDE Alcon April 2008
40
Portazza 18 NECITUMUMAB Eli Lilly November 2015
41
Priftin 18 RIFAPENTINE Hoechst Marion Roussel June 1998
42
Pulmozyme 18 DORNASE ALFA Genentech December 1996|March 1998
43
Qvar 18 BECLOMETHASONE DIPROPIONATE Ivax May 2002
44
Ragwitek 18 Merck April 2014
45
Rayos 18 PREDNISONE Horizon Pharma July of 2012
46
Remodulin 18 TREPROSTINIL United Therapeutics May 2002
47
Spiriva HandiHaler 18 TIOTROPIUM BROMIDE Boehringer Ingelheim February 2004
48
Synagis 18 PALIVIZUMAB MedImmune June 1998
49
Tagrisso 18 OSIMERTINIB MESYLATE AstraZeneca November 2015
50
Tequin 18 Bristol-Myers Squibb December, 1999

Drugs for Acral Lentiginous Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 21)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166
2 Immunologic Factors Phase 3,Phase 2,Phase 1
3 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
4 Immunoglobulins Phase 3,Phase 2,Phase 1
5 Antibodies Phase 3,Phase 2,Phase 1
6
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
7
Pembrolizumab Approved Phase 2 1374853-91-4
8
Nivolumab Approved Phase 2,Phase 1 946414-94-4
9
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
10
Maleic acid Experimental Phase 2 110-16-7 444266
11
Cediranib Investigational Phase 2 288383-20-0 9933475
12 tyrosine Phase 2
13 Angiogenesis Modulating Agents Phase 2
14 Angiogenesis Inhibitors Phase 2
15 Imatinib Mesylate Phase 2 220127-57-1 123596
16 Protein Kinase Inhibitors Phase 2
17
Ganciclovir Approved, Investigational Phase 1 82410-32-0 3454
18 Antiviral Agents Phase 1
19 Nucleic Acid Synthesis Inhibitors Phase 1
20 Anti-Infective Agents Phase 1
21 Ganciclovir triphosphate Phase 1

Interventional clinical trials:

(show all 17)
# Name Status NCT ID Phase Drugs
1 A Phase Ⅲ Study to Investigate JS001 Versus Dacarbazine as the First Line Therapy for Unresectable or Metastatic Melanoma Recruiting NCT03430297 Phase 3 Dacarbazine 1000mg/m2 Q3W
2 A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread Completed NCT01395121 Phase 2 nilotinib
3 SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma Completed NCT00577382 Phase 2 Sunitinib
4 Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Completed NCT00470470 Phase 2 imatinib mesylate
5 AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma Completed NCT00243061 Phase 2 cediranib maleate
6 Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma Recruiting NCT02875132 Phase 2 pembrolizumab
7 A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab Recruiting NCT02978443 Phase 2 Nivolumab;Ipilimumab
8 Nivolumab With or Without Ipilimumab or Relatlimab Before Surgery in Treating Patients With Stage IIIB-IV Melanoma That Can Be Removed by Surgery Recruiting NCT02519322 Phase 2
9 Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery Recruiting NCT03698019 Phase 2
10 Dinaciclib in Treating Patients With Stage IV Melanoma Active, not recruiting NCT00937937 Phase 2 Dinaciclib
11 Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery Active, not recruiting NCT00700882 Phase 2 dasatinib
12 Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma Terminated NCT01120275 Phase 2 gamma-secretase/Notch signalling pathway inhibitor RO4929097
13 Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma Terminated NCT01092728 Phase 2 Dasatinib
14 Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma Completed NCT00005057 Phase 1 ganciclovir
15 Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease Recruiting NCT03025256 Phase 1
16 Study of Families With Melanoma Recruiting NCT00445783
17 French Clinical Datbase of Melanoma Patients (RIC-Mel) Recruiting NCT03315468

Search NIH Clinical Center for Acral Lentiginous Melanoma

Genetic Tests for Acral Lentiginous Melanoma

Anatomical Context for Acral Lentiginous Melanoma

MalaCards organs/tissues related to Acral Lentiginous Melanoma:

41
Skin, Brain, Lung, Bone, Thyroid, Smooth Muscle, Myeloid

Publications for Acral Lentiginous Melanoma

Articles related to Acral Lentiginous Melanoma:

(show top 50) (show all 146)
# Title Authors Year
1
High density of M2-macrophages in acral lentiginous melanoma compared to superficial spreading melanoma. ( 29415335 )
2018
2
Acral lentiginous melanoma. ( 29900875 )
2018
3
Acral Lentiginous Melanoma Is Associated with Certain Poor Prognostic Histopathological Factors but May Not be Correlated with Nodal Involvement, Recurrence, and a Worse Survival. ( 29860247 )
2018
4
Metastatic acral lentiginous melanoma in a tertiary referral center in Switzerland: a systematic analysis. ( 29847461 )
2018
5
Prognostic features for acral lentiginous melanoma. ( 29441559 )
2018
6
Clinical features and prognosis of Asian patients with acral lentiginous melanoma who have nodal nevi in their sentinel lymph node biopsy specimen. ( 29673774 )
2018
7
Acral lentiginous melanoma in the Turkish population and a new dermoscopic clue for the diagnosis. ( 29785333 )
2018
8
Diagnosis and Management of Acral Lentiginous Melanoma. ( 29951919 )
2018
9
Feasibility of IMP-3 as an Invasiveness Marker for Acral Lentiginous Melanoma. ( 30065600 )
2018
10
Strategies for Reducing Diagnostic Delay in Acral Lentiginous Melanoma. ( 30122615 )
2018
11
Acral Lentiginous Melanoma: Survival Analysis of 715 Cases. ( 30221995 )
2018
12
Efficacy of nivolumab monotherapy against acral lentiginous melanoma and mucosal melanoma in Asian patients. ( 30447078 )
2018
13
Multiple Primary Acral Lentiginous Melanoma on the Feet Developing in Lesions of Nagashima-type Palmoplantar Keratoderma. ( 28224164 )
2017
14
Acral Lentiginous Melanoma, Indolent Subtype Diagnosed by En Bloc Excision: A Case Report. ( 28566910 )
2017
15
Acral lentiginous melanoma versus other melanoma: A single-center analysis in Japan. ( 28342269 )
2017
16
Tumor infiltrating lymphocytes in acral lentiginous melanoma: a study of a large cohort of cases from Latin America. ( 28577153 )
2017
17
Insulin-Like Growth Factor-II mRNA-Binding Protein 3 as a Novel Prognostic Biomarker for Acral Lentiginous Melanoma. ( 29048737 )
2017
18
Intracorneal Hematoma Showing Clinical and Dermoscopic Features of Acral Lentiginous Melanoma. ( 28567312 )
2017
19
The role of access to care in acral lentiginous melanoma survival. ( 28833024 )
2017
20
Prognostic factors and survival in acral lentiginous melanoma. ( 28432682 )
2017
21
Acral lentiginous melanoma - a skin cancer with unfavourable prognostic features. A study of the German Central Malignant Melanoma Registry (CMMR) in 2050 patients. ( 28707317 )
2017
22
Overexpression of Human Leukocyte Antigen-G and Interleukin 10 in acral lentiginous melanoma. ( 28587737 )
2017
23
Double Primary Acral Lentiginous Melanoma of both Soles. ( 28223769 )
2017
24
Acral lentiginous melanoma with dematiaceous fungal elements of Chaetomium globosum: A saprophytism or coexistence of superficial phaeohyphomycosis? ( 28836689 )
2017
25
Hidden acral lentiginous melanoma with cutaneous metastases masquerading as Kaposi's sarcoma in an HIV-positive Indian man. ( 26838298 )
2016
26
Survival of acral lentiginous melanoma in the National Cancer Institute of Colombia. ( 27518480 )
2016
27
Acral Lentiginous Melanoma. ( 26601870 )
2016
28
Histopathological diagnosis of acral lentiginous melanoma in early stages. ( 27601330 )
2016
29
Amelanotic acral lentiginous melanoma mimicking diabetic ulcer: a challenge to diagnose and treat. ( 26679765 )
2016
30
Acral lentiginous melanoma with multiple brain metastases in an Indian male. ( 27559525 )
2016
31
Insulin-Like Growth Factor II mRNA-Binding Protein 3 Expression Correlates with Poor Prognosis in Acral Lentiginous Melanoma. ( 26796627 )
2016
32
Rare cause of non-healing foot wound - acral lentiginous melanoma. Case Report. ( 26994380 )
2016
33
Erratum to «Laryngeal metastases of acral lentiginous melanoma: Narrow band imaging». ( 27393792 )
2016
34
Reflectance confocal microscopy features of acral lentiginous melanoma: a comparative study with acral nevi. ( 26428577 )
2015
35
MAP Kinase Pathways: Molecular Roads to Primary Acral Lentiginous Melanoma. ( 26588333 )
2015
36
IMAGES IN CLINICAL MEDICINE. Acral Lentiginous Melanoma. ( 26535515 )
2015
37
Acral lentiginous melanoma of the foot misdiagnosed as a traumatic ulcer a cautionary case. ( 25815661 )
2015
38
The distribution pattern of HMB-45-positive cells is helpful for the diagnosis of early acral lentiginous melanoma in situ. ( 25773399 )
2015
39
Focal invasiveness in complete histological analyses of a large acral lentiginous melanoma. ( 26088594 )
2015
40
Reconstruction of large wounds using a combination of negative pressure wound therapy and punch grafting after excision of acral lentiginous melanoma on the foot. ( 26173565 )
2015
41
Screening for Acral Lentiginous Melanoma in Dark-Skinned Individuals. ( 26083954 )
2015
42
Acral lentiginous melanoma: who benefits from sentinel lymph node biopsy? ( 25455840 )
2015
43
Laryngeal metastases of acral lentiginous melanoma: Narrow band imaging. ( 25488159 )
2014
44
Acral lentiginous melanoma: indolent subtype with long radial growth phase. ( 24556899 )
2014
45
Acral Lentiginous Melanoma - Misdiagnosis, referral delay and 5 years specific survival according to site. ( 25027337 )
2014
46
Comparison of dermatoscopic images of acral lentiginous melanoma and acral melanocytic nevus occurring on body weight-bearing areas. ( 25396085 )
2014
47
TERT promoter mutation is uncommon in acral lentiginous melanoma. ( 24588324 )
2014
48
Indolent Subtype Acral Lentiginous Melanoma With Long Radial Growth Phase: A Dermatopathological Pitfall. ( 25072690 )
2014
49
Prognostic and Clinicopathologic Associations of BRAF Mutation in Primary Acral Lentiginous Melanoma in Korean Patients: A Preliminary Study. ( 24882974 )
2014
50
Recurrent acral lentiginous melanoma in situ suggesting the field cell theory. ( 25473243 )
2014

Variations for Acral Lentiginous Melanoma

Cosmic variations for Acral Lentiginous Melanoma:

9 (show top 50) (show all 155)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM1166809 PTEN skin,acral,malignant melanoma,acral lentiginous c.333G>A p.W111* 10:87933092-87933092 22
2 COSM562 NRAS skin,acral,malignant melanoma,acral lentiginous c.34G>T p.G12C 1:114716127-114716127 22
3 COSM6503445 KIT skin,acral,malignant melanoma,acral lentiginous c.1658A>C p.Y553S 4:54727426-54727426 22
4 COSM1290 KIT skin,acral,malignant melanoma,acral lentiginous c.1727T>C p.L576P 4:54727495-54727495 22
5 COSM1257 KIT skin,acral,malignant melanoma,acral lentiginous c.1679T>A p.V560D 4:54727447-54727447 22
6 COSM235682 KIT skin,acral,malignant melanoma,acral lentiginous c.1965T>G p.N655K 4:54728096-54728096 22
7 COSM1430154 KIT skin,acral,malignant melanoma,acral lentiginous c.1715A>G p.D572G 4:54727483-54727483 22
8 COSM6503446 KIT skin,acral,malignant melanoma,acral lentiginous c.1733A>G p.Y578C 4:54727501-54727501 22
9 COSM1255 KIT skin,acral,malignant melanoma,acral lentiginous c.1676T>C p.V559A 4:54727444-54727444 22
10 COSM18682 KIT skin,acral,malignant melanoma,acral lentiginous c.2468A>G p.Y823C 4:54733176-54733176 22
11 COSM476 BRAF skin,acral,malignant melanoma,acral lentiginous c.1799T>A p.V600E 7:140753336-140753336 22
12 COSM460 BRAF skin,acral,malignant melanoma,acral lentiginous c.1406G>C p.G469A 7:140781602-140781602 22
13 COSM6951885 SETD2 skin,subungual,malignant melanoma,acral lentiginous c.3083C>G p.S1028C 3:47113999-47113999 16
14 COSM776 PIK3CA skin,subungual,malignant melanoma,acral lentiginous c.3140A>T p.H1047L 3:179234297-179234297 16
15 COSM6925493 PIK3C2G skin,subungual,malignant melanoma,acral lentiginous c.2381G>A p.W794* 12:18424039-18424039 16
16 COSM565 NRAS skin,subungual,malignant melanoma,acral lentiginous c.35G>C p.G12A 1:114716126-114716126 16
17 COSM6945207 NOTCH1 skin,subungual,malignant melanoma,acral lentiginous c.5828C>T p.A1943V 9:136500658-136500658 16
18 COSM6925488 MUTYH skin,subungual,malignant melanoma,acral lentiginous c.1435C>A p.H479N 1:45331214-45331214 16
19 COSM6925489 MSH6 skin,subungual,malignant melanoma,acral lentiginous c.3731T>A p.L1244* 2:47806288-47806288 16
20 COSM6951887 ERBB3 skin,subungual,malignant melanoma,acral lentiginous c.3158G>C p.G1053A 12:56100202-56100202 16
21 COSM6951883 BARD1 skin,subungual,malignant melanoma,acral lentiginous c.1232C>T p.P411L 2:214780642-214780642 16
22 COSM6915212 AXL skin,subungual,malignant melanoma,acral lentiginous c.1934C>A p.A645E 19:41253633-41253633 16
23 COSM6925490 skin,subungual,malignant melanoma,acral lentiginous c.688C>T p.R230* 3:179201415-179201415 16
24 COSM6945206 skin,subungual,malignant melanoma,acral lentiginous c.5828C>T p.A1943V 9:136500658-136500658 16
25 COSM94987 skin,subungual,malignant melanoma,acral lentiginous c.3140A>T p.H1047L 3:179234297-179234297 16
26 COSM6951884 skin,subungual,malignant melanoma,acral lentiginous c.4592C>G p.S1531C 3:47113999-47113999 16
27 COSM6915211 skin,subungual,malignant melanoma,acral lentiginous c.1961C>A p.A654E 19:41253633-41253633 16
28 COSM6951886 skin,subungual,malignant melanoma,acral lentiginous c.3158G>C p.G1053A 12:56100202-56100202 16
29 COSM6951882 skin,subungual,malignant melanoma,acral lentiginous c.1232C>T p.P411L 2:214780642-214780642 16
30 COSM6925492 skin,subungual,malignant melanoma,acral lentiginous c.2504G>A p.W835* 12:18424039-18424039 16
31 COSM6925491 skin,subungual,malignant melanoma,acral lentiginous c.2381G>A p.W794* 12:18424039-18424039 16
32 COSM6939025 TP63 skin,NS,malignant melanoma,acral lentiginous c.1510C>G p.P504A 3:189889342-189889342 14
33 COSM29529 RB1 skin,NS,malignant melanoma,acral lentiginous c.1411C>T p.Q471* 13:48380074-48380074 14
34 COSM5413434 RAF1 skin,NS,malignant melanoma,acral lentiginous c.1472C>T p.T491I 3:12585745-12585745 14
35 COSM6936562 RAF1 skin,NS,malignant melanoma,acral lentiginous c.626T>C p.L209P 3:12606255-12606255 14
36 COSM6889946 PTPRT skin,NS,malignant melanoma,acral lentiginous c.2431G>A p.E811K 20:42199366-42199366 14
37 COSM6936567 PTPRS skin,NS,malignant melanoma,acral lentiginous c.3707T>C p.L1236P 19:5219997-5219997 14
38 COSM6943320 PTCH1 skin,NS,malignant melanoma,acral lentiginous c.344G>T p.G115V 9:95506457-95506457 14
39 COSM6921633 PRKN skin,NS,malignant melanoma,acral lentiginous c.1210G>A p.E404K 6:161360163-161360163 14
40 COSM6954881 POLE skin,NS,malignant melanoma,acral lentiginous c.3541A>G p.K1181E 12:132657177-132657177 14
41 COSM6921634 PMS2 skin,NS,malignant melanoma,acral lentiginous c.640G>A p.V214M 7:5999173-5999173 14
42 COSM6943848 PLCG2 skin,NS,malignant melanoma,acral lentiginous c.3094G>A p.G1032R 16:81937799-81937799 14
43 COSM228367 PIK3CB skin,NS,malignant melanoma,acral lentiginous c.3200A>T p.D1067V 3:138655402-138655402 14
44 COSM6922385 NTRK3 skin,NS,malignant melanoma,acral lentiginous c.1831G>A p.D611N 15:87933070-87933070 14
45 COSM6914116 NTRK2 skin,NS,malignant melanoma,acral lentiginous c.2219G>T p.S740I 9:85020252-85020252 14
46 COSM583 NRAS skin,NS,malignant melanoma,acral lentiginous c.182A>T p.Q61L 1:114713908-114713908 14
47 COSM3724522 NRAS skin,NS,malignant melanoma,acral lentiginous c.184G>C p.E62Q 1:114713906-114713906 14
48 COSM584 NRAS skin,NS,malignant melanoma,acral lentiginous c.182A>G p.Q61R 1:114713908-114713908 14
49 COSM573 NRAS skin,NS,malignant melanoma,acral lentiginous c.38G>A p.G13D 1:114716123-114716123 14
50 COSM566 NRAS skin,NS,malignant melanoma,acral lentiginous c.35G>T p.G12V 1:114716126-114716126 14

Expression for Acral Lentiginous Melanoma

Search GEO for disease gene expression data for Acral Lentiginous Melanoma.

Pathways for Acral Lentiginous Melanoma

Pathways related to Acral Lentiginous Melanoma according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.58 BRAF CDKN2A KIT MET NRAS PTEN
2
Show member pathways
13.48 BRAF CDKN2A KIT MET NRAS PTEN
3
Show member pathways
13.45 BRAF CDKN2A KIT MET NRAS
4
Show member pathways
13.03 BRAF KIT MET NRAS
5
Show member pathways
12.78 BRAF KIT MET NRAS PTEN
6
Show member pathways
12.71 BRAF KIT MET NRAS
7
Show member pathways
12.7 BRAF MET NRAS PTEN
8
Show member pathways
12.69 BRAF MET NRAS PTEN
9
Show member pathways
12.64 KIT MET NRAS PTEN TERT
10 12.57 BRAF KIT MET NRAS
11
Show member pathways
12.53 BRAF KIT MET NRAS
12
Show member pathways
12.52 KIT MET NRAS PTEN
13
Show member pathways
12.51 BRAF CDKN2A KIT NRAS PTEN
14
Show member pathways
12.5 BRAF MET NRAS PTEN
15
Show member pathways
12.39 BRAF CDKN2A MET NRAS PTEN
16 12.3 CDKN2A MET NRAS PTEN
17
Show member pathways
12.29 BRAF MET NRAS
18
Show member pathways
12.27 BRAF MET NRAS PTEN
19 12.24 CDKN2A NRAS TERT
20 12.22 BRAF CDKN2A KIT MET NRAS PTEN
21
Show member pathways
12.2 BRAF NRAS PTEN
22
Show member pathways
12.2 BRAF KIT MET NRAS
23
Show member pathways
12.14 BRAF CDKN2A KIT NRAS
24 12.12 BRAF MET NRAS
25
Show member pathways
12.06 KIT MET TERT
26 12 CDKN2A NRAS PTEN
27 11.96 MET NRAS PTEN
28
Show member pathways
11.96 BRAF MET NRAS PTEN
29
Show member pathways
11.93 BRAF NRAS PTEN
30 11.83 CDKN2A NRAS PTEN
31
Show member pathways
11.83 BRAF CDKN2A KIT MET NRAS PTEN
32 11.76 BRAF CDKN2A PTEN
33
Show member pathways
11.64 BRAF KIT NRAS
34 11.6 BRAF CDKN2A NRAS PTEN
35 11.58 BRAF CDKN2A NRAS
36 11.46 BRAF NRAS
37 11.3 BRAF NRAS
38 11.27 KIT MET NRAS PTEN
39 11.2 BRAF NRAS
40 11.14 MET NRAS
41 11.13 NRAS PTEN

GO Terms for Acral Lentiginous Melanoma

Cellular components related to Acral Lentiginous Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasmic side of plasma membrane GO:0009898 8.62 KIT PTEN

Biological processes related to Acral Lentiginous Melanoma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.73 BRAF CDKN2A KIT PTEN
2 peptidyl-tyrosine phosphorylation GO:0018108 9.67 BRAF KIT MET
3 somatic stem cell population maintenance GO:0035019 9.57 BRAF KIT
4 visual learning GO:0008542 9.56 BRAF KIT
5 long-term synaptic potentiation GO:0060291 9.55 BRAF PTEN
6 cellular response to nerve growth factor stimulus GO:1990090 9.54 BRAF PTEN
7 negative regulation of endothelial cell apoptotic process GO:2000352 9.52 BRAF TERT
8 response to cadmium ion GO:0046686 9.51 KIT TERT
9 replicative senescence GO:0090399 9.48 CDKN2A TERT
10 somatic stem cell division GO:0048103 9.46 CDKN2A KIT
11 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.46 BRAF KIT MET PTEN
12 regulation of protein stability GO:0031647 9.43 CDKN2A PTEN TERT
13 obsolete negative regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031658 9.4 CDKN2A PTEN
14 regulation of axon regeneration GO:0048679 9.37 BRAF PTEN
15 myeloid progenitor cell differentiation GO:0002318 9.32 BRAF KIT
16 MAPK cascade GO:0000165 9.26 BRAF KIT MET NRAS
17 negative regulation of apoptotic process GO:0043066 9.02 BRAF KIT MET PTEN TERT

Molecular functions related to Acral Lentiginous Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.56 BRAF MET PTEN TERT
2 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.16 KIT MET
3 protein tyrosine kinase activity GO:0004713 9.13 BRAF KIT MET
4 nucleotide binding GO:0000166 8.92 BRAF KIT MET NRAS

Sources for Acral Lentiginous Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....